According to the investigation, Beijing Taibo Jixin Technology Development Co., Ltd. was established on May 25, 2006, with paid-in capital of RMB/kloc-0.00 million, with manager, executive director and supervisor Zhang.
On May 9, 2020, Beijing Taibo Jixin Technology Development Co., Ltd. was listed as the "executor" by Beijing No.1 Intermediate People's Court, with the execution target of 16689598.0. From the perspective of equity relationship, Beijing North Gene Biotechnology Co., Ltd. and Beijing Taibo Jixin Technology Development Co., Ltd. are not related.
However, according to official website of Northern Gene, Northern Gene is a brand of Taibo Jixin Company, and its series of health products adopt a unique O2O fission model, realizing the whole network coverage of distribution channels. Taibo Jixin is the manufacturer and sole distributor of "Northern Gene Small Molecular Peptides".
In July this year, according to China Quality News Network, 690 yuan, a dealer named Yan, subscribed for 1 box peptide as the first-level agent of Northern Gene, 6 boxes of peptides at RMB 3,640 as the intermediate agent, and 10720/box peptide as the senior agent, and recommended two agents to refund their money. The bonus is 40% of the profit of the sales prize (direct promotion prize) (net turnover × 70 %× 40%); Performance award can get 20% profit (collision prevention); The balance prize (collision prize) can get 42% of the first-tier profit and 28% or more of the second-tier profit.